Wyllie et al developed an index for predicting risk of 6-month mortality in a patient with thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS). This can help identify a patient who may benefit from more aggressive management or a novel therapy. The authors are from the University of Western Ontario and University of Ottawa in Canada.
